Skip to main content
Evidence Snapshot

Type-2 angiotensin II receptor

CHEMBL4607 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:17:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4607
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Type-2 angiotensin II receptor as ChEMBL target CHEMBL4607, mapped to UniProt P50052. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Type-2 angiotensin II receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4607
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P50052
Type-2 angiotensin II receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Type-2 angiotensin II receptor matters

As of 2026-09-14

Type-2 angiotensin II receptor is reviewed as Type-2 angiotensin II receptor (UniProt P50052); Type-2 angiotensin II receptor shows clinical signal disease relevance led by diabetic neuropathy. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 11 approved drugs, 1798 compounds, and 164 assays, with lead potency reaching pChEMBL 10.1.

Disease context
diabetic neuropathy

Type-2 angiotensin II receptor shows clinical signal disease relevance led by diabetic neuropathy. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include OLODANRIGAN.

Start review with diabetic neuropathy because it currently carries clinical signal support. Linked drugs include OLODANRIGAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 1798 compounds, and 164 assays for this target. The dominant activity type is IC50. CHEMBL1791308 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL1791308 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Type-2 angiotensin II receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P50052, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why diabetic neuropathy is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1798
Total Compounds
164
Total Assays
11
Approved Drugs
IC50: 1562.0, KI: 1111.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1791308
 10.1 Ki —
No preferred name
CHEMBL385433
 10.1 IC50 —
No preferred name
CHEMBL408403
 10.1 IC50 Approved
No preferred name
CHEMBL2392353
 10.0 Ki —
No preferred name
CHEMBL338027
 9.9 IC50 —

Approved Drugs

Structure Compound First Approval
ANGIOTENSIN II
CHEMBL408403
 2017
AZILSARTAN MEDOXOMIL
CHEMBL2028661
 2011
TELMISARTAN
CHEMBL1017
 1998
LOSARTAN
CHEMBL191
 1995
SARALASIN
CHEMBL938
 1982
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:17:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4607